| Name | Title | Contact Details |
|---|
Arkuda Therapeutics is a biotechnology company applying insights into lysosomal biology to drive the development of medicines to change the trajectory of neurodegenerative disease. Arkuda`s lead program ARKD-104 aims to correct progranulin deficiency and lysosomal dysfunction in patients with GRN-related frontotemporal dementia (FTD-GRN), a genetically-defined subtype of frontotemporal dementia caused by an autosomal dominant mutation in the progranulin (GRN) gene. The company is further exploring the therapeutic potential of its molecules in other neurodegenerative diseases where genetic links to dysfunction in progranulin biology have been established, including Alzheimer`s Disease and Parkinson`s Disease. Arkuda is backed by leading investors including Atlas Venture, Cormorant Asset Management, Pfizer Ventures, funds managed by Tekla Capital Management LLC, Mission BioCapital, and Eli Lilly and Company.
Ariana is a spin-off of the prestigious Pasteur Institute offering a unique and powerful association rules-based analytical approach to clinical datasets and biomarker discovery that is complementary to statistical analysis.
GTx, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
Aligos Therapeutics is discovering and developing new classes of compounds that interact directly with disease causing molecules. These approaches are targeting viral nucleic acids and their encoded proteins, as well as oncogenes and their resultant proteins. The company is also pursuing novel therapeutic agents aimed at activation of the immune system to resolve diseases that cause significant morbidity and mortality.
Soliance is a Allendale, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.